Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Foppoli

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Blood Advances|May 17, 2022
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphomaAndrés J M Ferreri, Piera Angelillo, Federico Erbella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II TrialAndrés J M Ferreri, Giovanni Donadoni, Maria Giuseppina Cabras, et al.
Blood|May 24, 2019
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphomaAndrés J M Ferreri, Teresa Calimeri, Gian Marco Conte, et al.
Blood Advances|August 9, 2020
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trialAndrés J M Ferreri, Teresa Calimeri, Maurilio Ponzoni, et al.
Hematological Oncology|May 2, 2020
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantationAndrés J M Ferreri, Marianna Sassone, Piera Angelillo, et al.
Lancet (London, England)|September 22, 2009
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialAndrés J M Ferreri, Michele Reni, Marco Foppoli, et al.
British Journal of Haematology|February 23, 2021
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective studyAndrés J M Ferreri, Teresa Calimeri, Paolo Lopedote, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Blood Advances|May 17, 2022
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphomaAndrés J M Ferreri, Piera Angelillo, Federico Erbella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II TrialAndrés J M Ferreri, Giovanni Donadoni, Maria Giuseppina Cabras, et al.
Blood|May 24, 2019
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphomaAndrés J M Ferreri, Teresa Calimeri, Gian Marco Conte, et al.
Blood Advances|August 9, 2020
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trialAndrés J M Ferreri, Teresa Calimeri, Maurilio Ponzoni, et al.
Hematological Oncology|May 2, 2020
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantationAndrés J M Ferreri, Marianna Sassone, Piera Angelillo, et al.
Lancet (London, England)|September 22, 2009
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialAndrés J M Ferreri, Michele Reni, Marco Foppoli, et al.
British Journal of Haematology|February 23, 2021
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective studyAndrés J M Ferreri, Teresa Calimeri, Paolo Lopedote, et al.
Pageof 3